NK cell infusion for children and young adults with sarcoma
Part of Cancer clinical trials.
This trial tests an infusion of activated NK cells (a type of immune cell) to treat sarcomas that are still detectable or not responding well to standard treatment. If you qualify, you may receive this cell therapy while doctors closely check your organ function and heart strength.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between birth and age 30 and have a cancer called sarcoma
- After standard treatments, your scans show leftover cancer, or the cancer is stable/minimal but chemotherapy didn’t help (or was poorly tolerated)
- You need to be strong enough for treatment (Lansky/Karnofsky score above 60%)
- Your liver, kidney, and breathing function must be mildly affected at most
- Your heart pumping strength (ejection fraction) must be above 39%
- You must have a matching half-matched donor from family (parent or sibling)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special type of immune cell (called a CAR T-cell) that is trained to attack sarcoma cells. It is for children, teens, and young adults up to age 40 whose sarcoma has not responded to standard therapy. The treatment is given directly into the tumor, and the goal is to see if it is safe and how well it works.
This trial tests a new treatment using natural killer (NK) cells, a type of immune cell, to fight advanced solid tumors. It may be an option if standard treatments have stopped working or are not available.
This early-phase trial studies a type of immune cell treatment (NK cells) made from donor cells, given with chemotherapy drugs gemcitabine and docetaxel. It’s for children and young adults whose bone or soft tissue sarcoma has come back or hasn’t responded to prior treatment.
This trial tests whether giving immune cells called NK cells from donated umbilical cord blood can help children and teens with high-risk or returning soft tissue sarcoma. The goal is to see if it is safe and effective when other treatments have been tried.
This trial tests a new type of immune cell called natural killer (NK) cells from healthy donors to treat neuroblastoma that has not responded to standard treatments. The goal is to see if these cells can help shrink or control the cancer.
This trial tests a new natural killer (NK) cell therapy from donated umbilical cord blood for children with high-risk neuroblastoma that has come back or not responded to treatment. The goal is to see if this immune cell therapy is safe and can help fight the cancer.
Hear when a new Malignant Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.